# A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy

> **NCT07676266** · PHASE1 · NOT_YET_RECRUITING · sponsor: **The Affiliated Hospital of Qingdao University** · enrollment: 18 (estimated)

## Conditions studied

- Multiple Sclerosis (MS)
- Myasthenia Gravis (MG)
- Neuromyelitis Optica Spectrum Disorder
- Systemic Lupus Erythematosus
- Systemic Sclerosis
- Immune-Mediated Necrotizing Myopathy

## Interventions

- **BIOLOGICAL:** CD20/BCMA-directed CAR-T cells Autologous 2nd generation

## Key facts

- **NCT ID:** NCT07676266
- **Lead sponsor:** The Affiliated Hospital of Qingdao University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07
- **Primary completion:** 2027-11
- **Final completion:** 2028-10
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-06-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07676266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07676266, "A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07676266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*